945363-51-9 Usage
Description
1-(4-methoxyphenyl)-1,5,6,7-tetrahydro-4H-indazol-4-one, also known as Indoprofen, is a chemical compound belonging to the class of indazole derivatives. It features a tetrahydroindazole core structure and is recognized for its anti-inflammatory and analgesic properties. Indoprofen is a nonsteroidal anti-inflammatory drug (NSAID) that is effective in alleviating pain and reducing inflammation by inhibiting the production of prostaglandins, which are molecules that contribute to pain, fever, and inflammation in the body.
Uses
Used in Pharmaceutical Industry:
1-(4-methoxyphenyl)-1,5,6,7-tetrahydro-4H-indazol-4-one is used as an anti-inflammatory and analgesic agent for its ability to relieve pain and reduce inflammation. It is particularly effective in treating conditions such as arthritis, menstrual cramps, and other types of acute and chronic pain by targeting the prostaglandins responsible for these symptoms.
Used in Pain Management:
In the field of pain management, 1-(4-methoxyphenyl)-1,5,6,7-tetrahydro-4H-indazol-4-one is utilized as a nonsteroidal anti-inflammatory drug (NSAID) to provide relief from various types of pain, including musculoskeletal, postoperative, and other forms of pain that arise from inflammation or injury.
Used in Inflammation Treatment:
1-(4-methoxyphenyl)-1,5,6,7-tetrahydro-4H-indazol-4-one is employed as an anti-inflammatory agent in the treatment of various inflammatory conditions. By inhibiting the production of prostaglandins, it helps to control the inflammatory response and alleviate the associated symptoms.
Check Digit Verification of cas no
The CAS Registry Mumber 945363-51-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,4,5,3,6 and 3 respectively; the second part has 2 digits, 5 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 945363-51:
(8*9)+(7*4)+(6*5)+(5*3)+(4*6)+(3*3)+(2*5)+(1*1)=189
189 % 10 = 9
So 945363-51-9 is a valid CAS Registry Number.
945363-51-9Relevant articles and documents
Pyrazolo[3,4-h]quinolines promising photosensitizing agents in the treatment of cancer
Spanò, Virginia,Parrino, Barbara,Carbone, Anna,Montalbano, Alessandra,Salvador, Alessia,Brun, Paola,Vedaldi, Daniela,Diana, Patrizia,Cirrincione, Girolamo,Barraja, Paola
, p. 334 - 351 (2015/09/01)
A new series of pyrazolo[3,4-h]quinolines, heteroanalogues of angelicin was conveniently prepared with a broad substitution pattern. A large number of derivatives was obtained and the cellular photocytotoxicity was evaluated in vitro against 5 different h
Identification, synthesis, and pharmacological evaluation of tetrahydroindazole based ligands as novel antituberculosis agents
Guo, Songpo,Song, Yang,Huang, Qingqing,Yuan, Hai,Wan, Baojie,Wang, Yuehong,He, Rong,Beconi, Maria G.,Franzblau, Scott G.,Kozikowski, Alan P.
experimental part, p. 649 - 659 (2010/06/19)
The resurgence of tuberculosis (TB), the incidence of drug-resistant strains of Mycobacterium tuberculosis (MTB), and the coinfection between TB and HIV have led to serious infections, high mortality, and a global health threat, resulting in the urgent search for new classes of antimycobacterial agents. Herein, we report the identification of a novel class of tetrahydroindazole based compounds as potent and unique inhibitors of MTB. Compounds 6a, 6m, and 6q exhibited activity in the low micromolar range against replicating Mycobacterium tuberculosis (R-TB) phenotype, with minimum inhibitory concentrations (MICs) of 1.7, 1.9, and 1.9 μM, respectively, while showing no toxicity to Vero Ccells. Moreover, studies aimed to assess the in vitro metabolic stability of 6a and 6m in mouse liver microsomes and in vivo pharmacokinetic profiles in plasma levels gave satisfactory results. This research suggests that tetrahydroindazole based anti-TB compounds can serve as a promising lead scaffold in developing new drugs to combat tuberculosis infections.
